

ASX ANNOUNCEMENT

16 July 2026

Allison Rossiter joins Clarity's Board of Directors

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that Ms Allison Rossiter has joined Clarity's Board of Directors as an independent Non-Executive Director.

Allison Rossiter is an experienced healthcare executive with 25 years of global leadership across diagnostics, pharmaceuticals and medical technology. She has held senior leadership roles across all three Roche divisions, Pharmaceuticals, Diagnostics and Diabetes Care, and has lived and worked in the UK, Canada, the US and Australia. As Managing Director of Roche Diagnostics Australia, she led a major organisational transformation and Roche's national COVID-19 testing response. Ms Rossiter was later with an Australian Securities Exchange (ASX) listed diagnostics company and was most recently employed at Novartis as Country President for Australia and New Zealand.

She began her career at Pfizer UK while completing a BSc (Hons) in Computing & Informatics at the University of Plymouth, before transitioning into healthcare leadership. A graduate of Oxford Saïd Business School, Ms Rossiter is a member of the Australian Institute of Company Directors and Young Presidents Organisation and serves as Chair of the Board of SwissCham. She is passionate about innovation and changing lives and believes in leading with curiosity, courage and integrity.

This appointment is aligned with Clarity's commitment to strong corporate governance. With the total number of Clarity Directors now being six, including two Executive Directors and four Non-Executive Directors, this change will result in an independent Director majority, in line with the *ASX Corporate Governance Principles and Recommendations*.

Clarity's Executive Chairperson, Dr Alan Taylor, commented, "We are very pleased to welcome Ali to the Board as an independent Non-Executive Director. The depth and breadth of her experience in the industry, in addition to her leadership expertise across three continents, are unique in the field, and we are honoured to have this calibre of talent on our Board. Ali's extensive knowledge of the commercial diagnostic space in particular will be invaluable to Clarity during this exciting phase of commercialisation of two of our diagnostic products into the oncology market. With our lead product, SAR-bisPSMA, positioned as a best-in-class next-generation diagnostic bound to dominate and further expand the blockbuster PSMA PET market, our team, collaborators and Board are as determined as ever to build a strong foundation for our seamless transition from an emerging biotech company generating high-quality data with an underlying commitment to the highest standard of research and development to a successful pharmaceutical company in oncology markets with high unmet needs."

Allison Rossiter said, "Clarity is entering a pivotal phase in its evolution — progressing from proprietary innovation at the bench to the cusp of commercialisation in a significant global market. I am delighted to join the Board at such an important time for the Company. My initial focus will be on the lead diagnostic, SAR-bisPSMA, which continues to demonstrate exceptional efficacy compared with current standard-of-care. It is remarkable that the multi-billion-dollar PSMA imaging market remains dominated by products with such low sensitivity — something almost unheard of in diagnostics. With strong and growing data supporting commercialisation pathways in the US, and a highly capable team with world-class expertise, Clarity is well positioned to lead this category.

"The strength and consistency of the SAR-bisPSMA data underscores the potential for a meaningful step-change in prostate cancer imaging. The opportunity to contribute to the development of more accurate, reliable and accessible diagnostics is one I take very seriously.

"This work is also personally significant. My family has been directly impacted by prostate cancer — my father lives with the disease, and the future risk to my three sons is very real. I am hopeful that the next generation of diagnostic and therapeutic innovation will deliver substantial improvements for patients, families and clinicians. I am proud to join Clarity at this stage of its journey and to support the advancement of better diagnostics and therapies for people living with cancer."

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.

www.claritypharmaceuticals.com

For more information, please contact:**Clarity Pharmaceuticals**

Dr Alan Taylor

Executive Chairperson

ataylor@claritypharm.com

Lisa Sadetskaya

Director, Corporate Communications

lisa@claritypharm.com

This announcement has been authorised for release by the Executive Chairperson.